SwiftPharma is a biotechnology pioneer specializing in CDMO services, driving innovation in the development and production of animal-free proteins. By addressing market dynamics and customer needs, the company delivers cutting-edge solutions that create meaningful impact in the present and pave the way for a sustainable future.
At the core of SwiftPharma’s operations is the proprietary HyperXpress® bioplatform, which leverages plants as mini-bioreactors. This technology enables the rapid, scalable, and precise production of low-cost proteins. Complemented by a unique molecular toolbox and flexible infrastructure, SwiftPharma produces a diverse portfolio of protein classes, simplifying processes and accelerating development timelines.
The company is committed to advancing biomanufacturing through continuous flow operations, ensuring that residual biomass is utilized to promote the bioeconomy. By integrating sustainable practices, SwiftPharma maximizes the value of its processes, yielding byproducts such as biochar, syngas, cellulose nanocrystals, and a range of other high-value products. These efforts enhance process economics while contributing to circular bioeconomic initiatives.
SwiftPharma’s mission is to enhance lives through innovative biodesign, working with forward-thinking partners to transform the future of synthetic biology and redefine the limits of what is possible in sustainable manufacturing.
OTHER INDUSTRIAL MEMBERS
Other research groups